Recent News

• 12.20.2024 - Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
• 12.05.2024 - Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
• 12.03.2024 - Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

Recent Filings

• 02.07.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 01.27.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 01.27.2025 - EFFECT Notice of Effectiveness
• 01.15.2025 - S-3 Registration statement under Securities Act of 1933
• 01.08.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.02.2025 - 4 Statement of changes in beneficial ownership of securities
• 12.23.2024 - 8-K Current report
• 12.23.2024 - 424B5 Prospectus [Rule 424(b)(5)]
• 12.06.2024 - EX-99.1 EX-99.1